D. Chan

K. Kinzler, B. Vogelstein, D. Chan, 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry

D. Chan, Zhen Zhang, J. Rosenzweig, 2004, Clinical Cancer Research.

Characterization of Renal Allograft Rejection by Urinary Proteomic Analysis

D. Chan, Zhen Zhang, A. Klein, 2003, Annals of surgery.

for the Detection of Early Stage Ovarian Cancer Three Biomarkers Identified from Serum Proteomic Analysis

R. Bast, E. Fung, D. Chan, 2004 .

Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies.

E. Petricoin, Yan Li, Yuan Tian, 2012, Journal of proteome research.

Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges

D. Chan, A. K. Füzéry, Joshua D Levin, 2013, Clinical Proteomics.

Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam principles)

Richard D. Smith, J. Yates, R. Moritz, 2012, Proteomics.

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.

D. Chan, A. Partin, P. Walsh, 1993, The Journal of urology.

Increased plasma DNA integrity in cancer patients.

D. Chan, I. Shih, L. Sokoll, 2003, Cancer research.

Cancer Proteomics: In Pursuit of “True” Biomarker Discovery

D. Chan, Zhen Zhang, 2005, Cancer Epidemiology Biomarkers & Prevention.

Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma.

Jeffrey R. Whiteaker, Ratna R. Thangudu, Samuel H. Payne, 2020, Cell reports.

Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer

Ronald J. Moore, Samuel H. Payne, Stefani N. Thomas, 2016, Cell.

Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays.

Jeffrey R. Whiteaker, Matthew R. Meyer, Stefani N. Thomas, 2016, Clinical chemistry.

Orthogonal Proteomic Platforms and Their Implications for the Stable Classification of High-Grade Serous Ovarian Cancer Subtypes

Stefani N. Thomas, R. Aebersold, D. Chan, 2019, bioRxiv.

Orthogonal Proteomic Platforms and Their Implications for the Stable Classification of High-Grade Serous Ovarian Cancer Subtypes

Ruedi Aebersold, Hui Zhang, Michael Schnaubelt, 2019, bioRxiv.

Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels*

Ronald J Moore, Vladislav A Petyuk, Feng Yang, 2014, Molecular & Cellular Proteomics.

Cardiac Troponin I Predicts Short-Term Mortality in Vascular Surgery Patients

Peter J. Pronovost, Todd Dorman, Lee A. Fleisher, 2002, Circulation.

Cancer Proteomics: Serum Diagnostics for Tumor Marker Discovery

Daniel W Chan, D. Chan, A. Rai, 2004, Annals of the New York Academy of Sciences.

Chapter 1 – General Principle of Immunoassay

D. Chan, 1987 .

Clinical instrumentation (immunoassay analyzers).

D. Chan, 1995, Analytical chemistry.

Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age.

A W Partin, D. Chan, W. Catalona, 1996, Urology.

The human proteome – a scientific opportunity for transforming diagnostics, therapeutics, and healthcare

Mark Gerstein, Marc Vidal, Matthias Mann, 2012, Clinical Proteomics.

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements.

L. Liotta, D. Chan, C. Sturgeon, 2008, Clinical chemistry.

Natural history of progression after PSA elevation following radical prostatectomy.

A W Partin, D. Chan, A. Partin, 1999, JAMA.

Classification of cancer types by measuring variants of host response proteins using SELDI serum assays

Xiao-Ying Meng, Zheng Wang, Daniel W Chan, 2005, International journal of cancer.

Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer

D. Chan, Hui Zhang, Jiang Qian, 2020, Nature Communications.

Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings.

D. Chan, P. Walsh, L. Sokoll, 1998, The Journal of urology.

Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer.

Lori J Sokoll, Hsueh-Wei Chang, Daniel W Chan, 2003, Journal of the National Cancer Institute.

Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors*

D. Chan, Hui Zhang, I. Shih, 2018, Molecular & Cellular Proteomics.

Cardiac troponin T and C-reactive protein as markers of acute cardiac allograft rejection.

D. Chan, J. Segal, R. Hruban, 2001, Clinica chimica acta; international journal of clinical chemistry.

Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma

Jeffrey R. Whiteaker, Dana R. Valley, Karna L. Robinson, 2020, Cell.

WHO first international standards for prostate-specific antigen: the beginning of the end for assay discrepancies?

D. Chan, L. Sokoll, Daniel W. Chan, 2000, Clinical chemistry.

Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma

Guo Ci Teo, Matthew A. Wyczalkowski, Andy T. Kong, 2019, Cell.

Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model.

D. Chan, W. Catalona, A. Partin, 1999, Urology.

Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis.

D. Tindall, D. Chan, W. Catalona, 1999, Urology.

Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging.

E. Metter, D. Chan, H. Carter, 2001, Urology.

Concentration of enzymatically active prostate‐specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models

D. Chan, L. Sokoll, J. Isaacs, 2001, The Prostate.

Comprehensive analysis of protein glycosylation by solid-phase extraction of N-linked glycans and glycosite-containing peptides

Paul Aiyetan, Hui Zhang, Daniel W Chan, 2016, Nature Biotechnology.

The Application of Clinical Proteomics to Cancer and other Diseases

D. Chan, Zhen Zhang, W. Clarke, 2003, Clinical chemistry and laboratory medicine.

Abstract 5123: Proteogenomic characterization reveals mitotic kinase and replication stress implicated in ovarian high-grade serous cancer

Li Ding, Henry Rodriguez, Jason E. McDermott, 2020 .

PROSTATE-SPECIFIC ANTIGEN: Its Discovery and Biochemical Characteristics

D. Chan, L. Sokoll, Daniel W. Chan, 1997 .

Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen.

J. Oesterling, D. Chan, P. Walsh, 1987, Clinical chemistry.

Multi-center analytical performance evaluation of the Access Hybritech® p2PSA immunoassay.

Corey M. Carlson, D. Chan, L. Sokoll, 2012, Clinica chimica acta; international journal of clinical chemistry.

Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.

D. Chan, A. Partin, L. Sokoll, 2004, Urology.

Natural History of Progression After PSA Elevation Following Radical Prostatectomy

D. Chan, A. Partin, P. Walsh, 1999 .

Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer.

D. Chan, Vinita Gupta, Danni Li, 2012, Clinica chimica acta; international journal of clinical chemistry.

Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer.

D. Chan, A. Partin, P. Walsh, 2001, Urology.

Plasma selenium level before diagnosis and the risk of prostate cancer development.

E. Metter, J. Brooks, D. Chan, 2001, The Journal of urology.

Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis.

T. Stamey, D. Chan, A. Partin, 2002, Urology.

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.

M. Kattan, D. Chan, A. Haese*, 2005, The Journal of urology.

The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer.

J. Pannek, D. Chan, A. Partin, 1996, Urology.

Intermittent cardiac troponin-I screening is an effective means of surveillance for a perioperative myocardial infarction.

D. Chan, L. Fleisher, J. Weiss, 2005, Journal of cardiothoracic and vascular anesthesia.

Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men.

D. Chan, A. Partin, L. Sokoll, 2002, Urology.

Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia.

J. Pannek, D. Chan, A. Partin, 1998, The Journal of urology.

Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis.

E. Metter, D. Chan, A. Partin, 1997, Urology.

The potential utility of a rapid CK-MB assay in evaluating emergency department patients with possible myocardial infarction.

D. Chan, G. Kelen, A. Guerci, 1991, Annals of emergency medicine.

Malignancy-associated endocrine disorders

D. Chan, L. Sokoll, D. Chan, 2021 .

Monitoring hepatocellular carcinoma by using a monoclonal immunoenzymometric assay for alpha-fetoprotein.

D. Chan, D. Bruzek, R. Rock, 1988, Clinical chemistry.

Validation of Serum Biomarkers That Complement CA19-9 in Detecting Early Pancreatic Cancer Using Electrochemiluminescent-Based Multiplex Immunoassays

D. Chan, Zhen Zhang, L. Sokoll, 2021, Biomedicines.

Identification of glycoproteins containing specific glycans using a lectin-chemical method.

Yan Li, D. Chan, Hui Zhang, 2015, Analytical chemistry.

Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses.

D. Chan, Zhen Zhang, R. Coleman, 2016, American journal of obstetrics and gynecology.

Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach*

Susan E. Abbatiello, S. Carr, R. Aebersold, 2014, Molecular & Cellular Proteomics.

Hybritech total and free prostate-specific antigen assays developed for the Beckman Coulter access automated chemiluminescent immunoassay system: a multicenter evaluation of analytical performance.

D. Chan, L. Sokoll, D. Bruzek, 2001, Clinical Chemistry.

Comparison of total prostate-specific antigen and derivative levels in a screening population of black, white, and Korean-American men.

D. Chan, A. Partin, L. Sokoll, 2003, Clinical prostate cancer.

Critical analysis of false elevations in PSA results reported with the abbott AxSYM assay

D. Chan, A. Partin, J. Nelson, 1999, The Prostate.

Bone to total alkaline phosphatase ratios improve sensitivity and specificity of bone alkaline phosphatase immunoassays.

D. Chan, L. Sokoll, M. Levine, 1997, Clinical biochemistry.

Identification of Biomarkers for Breast Cancer in Nipple Aspiration and Ductal Lavage Fluid

D. Chan, H. Kuerer, S. Sukumar, 2005, Clinical Cancer Research.

Identifying Markers for Pancreatic Cancer by Gene

B. Vogelstein, D. Chan, V. Velculescu, 2017 .

Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer.

E. Metter, D. Chan, A. Partin, 1996, Urology.

A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma

D. Chan, L. Sokoll, P. Hemken, 2011, Clinical chemistry and laboratory medicine.

in press-uncorrected proof A comparative evaluation of Golgi protein-73 , fucosylated hemopexin , a-fetoprotein , and PIVKA-II in the serum of patients with chronic hepatitis , cirrhosis , and hepatocellular carcinoma

D. Chan, L. Sokoll, P. Hemken, 2011 .

Development and analytical performance evaluation of an automated chemiluminescent immunoassay for pro-gastrin releasing peptide (ProGRP)

D. Chan, L. Sokoll, G. Beligere, 2009, Clinical chemistry and laboratory medicine.

Immunologic Approaches to Tumor Markers: Assays, Applications, and Discovery

D. Chan, A. Rai, D. Chan, 2006 .

Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration.

John T. Wei, D. Chan, W. Catalona, 2013, The Journal of urology.

Analytical and clinical performance characteristics of Hybritech's Tandem-R free PSA assay during a large multicenter clinical trial to determine the clinical utility of percentage of free prostate-specific antigen.

D. Chan, J. Beck, D. Lamb, 1999, Clinical chemistry.

Capillary prolactin measurement for diagnosis of seizures

D. Chan, R. Lesser, M. Bare, 1991, Annals of neurology.

Elevated urine thrombomodulin/creatinine ratio in severely preeclamptic pregnancies.

D. Chan, T. Johnson, C. Hsu, 1994, American journal of obstetrics and gynecology.

Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.

T. Stamey, D. Chan, A. Partin, 2003, The Journal of urology.

Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients.

D. Chan, L. Sokoll, M. Untch, 2003, Clinical laboratory.

The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia.

J. Oesterling, D. Chan, A. Partin, 1989, The Journal of urology.

Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal Instability

Li Ding, Molly Brewer, Rui Zhao, 2020, Cell reports medicine.

A new biomarker in monitoring breast cancer: CA 549.

D. Ettinger, D. Chan, R. Beveridge, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Monitoring breast cancer with CA 549.

D. Ettinger, D. Chan, R. Beveridge, 1988, Clinical chemistry.

Detection of Autoantibodies to Annexin A11 in Different Types of Human Cancer

Yuan Tian, D. Chan, Zhen Zhang, 2009, Clinical Proteomics.

Clinical Evaluation Comparing AxSYM® CA 15-3TM, IMx® CA 15-3 and Truquant® BRTM RIA

D. Chan, J. L. Cox, D. Bruzek, 1998, Tumor Biology.

Multicenter evaluation of the Bayer Immuno I CA 15-3 assay.

D. Chan, A. Wu, W. J. Allard, 1998, Clinical chemistry.

Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass.

E. Fung, D. Chan, Zhen Zhang, 2013, American journal of obstetrics and gynecology.

Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.

D. Chan, A. Partin, L. Sokoll, 2003, The Journal of urology.

Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer.

J. Pannek, D. Chan, A. Partin, 1997, Urology.

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis.

H. Klocker, D. Chan, A. Partin, 2003, Urology.

Influence of radical prostatectomy on serum hormone levels.

D. Chan, A. Partin, P. Walsh, 1998, The Journal of urology.

Longitudinal evaluation of serum androgen levels in men with and without prostate cancer

E. Metter, D. Chan, P. Walsh, 1995, The Prostate.

Clinical evaluation of the Elecsys total prostate-specific antigen assay on the Elecsys 1010 and 2010 systems.

D. Chan, A. Haese*, A. Partin, 2002, Clinical chemistry.

SCI€NTIFIC ADVANC€S The Prognostic Significance of Troponin I and soponin T

D. Chan, J. L. Cox, G. Kelen, 1998 .

Utility of Three-Protein Panels in the Separation of Aggressive Prostate Cancer from Non-Aggressive Tumors

D. Chan, Hui Zhang, Q. K. Li, 2021 .

Redesigned proficiency testing materials improve survey outcomes for prostate-specific antigen. A College of American Pathologists Ligand Assay Survey tool.

D. Chan, L. Sokoll, G. Klee, 2000, Archives of pathology & laboratory medicine.

A panel of biomarkers to improve specificity in presurgical assessment of adnexal masses for risk of ovarian malignancy.

D. Chan, Zhen Zhang, L. Sokoll, 2013 .

Expression and clinicopathological significance of oestrogen‐responsive ezrin–radixin–moesin‐binding phosphoprotein 50 in breast cancer

D. Chan, E. Gabrielson, Z. Zhang, 2007, Histopathology.

Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?

T. Stamey, D. Chan, A. Partin, 2002, Urology.

Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer

J. Pannek, D. Chan, A. Partin, 1998, Prostate Cancer and Prostatic Diseases.

Plasma Thrombomodulin Levels in Women with Systemic Lupus Erythematosus

D. Chan, M. Petri, T. Johnson, 1995, American journal of perinatology.

Laboratory and bedside evaluation of portable glucose meters.

D. Chan, J. Nichols, C. Howard, 1995, American journal of clinical pathology.

Myoglobin for early risk stratification of emergency department patients with possible myocardial ischemia.

D. Chan, G. Kelen, G. Green, 2000, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

D. Chan, J. Fozard, J. Epstein, 1997, JAMA.

A multiplex immunoassay of serum biomarkers for the detection of uveal melanoma

D. Chan, Zhen Zhang, L. Sokoll, 2019, Clinical Proteomics.

Elevated circulating thrombomodulin in severe preeclampsia.

D. Chan, F. Witter, T. Johnson, 1993, American journal of obstetrics and gynecology.

Bayer immuno 1™ PSA assay: An automated, ultrasensitive method to quantitate total PSA in serum

D. Chan, R. Vessella, W. J. Allard, 1998, Journal of clinical laboratory analysis.

Immunosensors—Principles and Applications to Clinical Chemistry

D. Chan, L. Sokoll, P. Luppa, 2002 .

Automated chemiluminescent immunoassay analyzers

D. Chan, L. Sokoll, Dai J. Li, 1998 .

Affinity chromatographic separation of alpha-fetoprotein variants: development of a mini-column procedure, and application to cancer patients.

D. Chan, Y. Miao, D. Chan, 1986, Clinical chemistry.

Increased Plasma DNA Integrity in Cancer Patients 1

D. Chan, I. Shih, L. Sokoll, 2003 .

Advances in mass spectrometry-based clinical biomarker discovery

Stefani N. Thomas, D. Chan, L. Sokoll, 2016, Clinical Proteomics.

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.

H. Nielsen, N. Brünner, R. Bast, 2008, Clinical chemistry.

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.

E. Metter, D. Chan, P. Walsh, 1992, JAMA.

Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly‐available database

Eugene A. Kapp, S. Hanash, R. Aebersold, 2005, Proteomics.

Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology.

Lori J Sokoll, David H Wilson, Alan W Partin, 2011, Clinical chemistry.

21 – AUTOMATION OF IMMUNOASSAYS

Daniel W. Chan, D. Chan, 1996 .

Specific binding proteins for human chorionic gonadotrophin in a patient with trophoblastic disease.

D. Chan, N. Rosenshein, M. J. Bill, 1981, American journal of clinical pathology.

Elevated serum human chorionic gonadotropin as evidence of secretory response in severe preeclampsia.

D. Chan, J. Repke, T. Johnson, 1994, American journal of obstetrics and gynecology.

National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Ovarian Cancer

R. Bast, D. Chan, I. Shih, 2006 .

Automated quantification of choriogonadotropin: analytical correlation between serum and urine with creatinine correction.

D. Chan, A. Wu, S. Wong, 1987, Clinical Chemistry.

Evaluation ofa Monoclonal lmmunoenzymometric AssayforAlpha- Fetoprotein

D. Chan, D. Bruzek, Martin Keisten, 1986 .

Prostate-specific antigen in men born with bladder exstrophy.

D. Chan, A. Partin, J. Epstein, 1997, Urology.

Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.

J. Oesterling, D. Chan, P. Walsh, 1988, The Journal of urology.

Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared.

J. Oesterling, D. Chan, P. Walsh, 1987, Clinical chemistry.

Breast cancer marker Ca549. A multicenter study.

M K Schwartz, D. Chan, A. Bhargava, 1994, American journal of clinical pathology.

Assessing tumors in living animals through measurement of urinary β-human chorionic gonadotropin

K. Kinzler, B. Vogelstein, D. Chan, 2000, Nature Medicine.

Improvement and Multicenter Evaluation of the Analytical Performance of an Automated Chemiluminescent Immunoassay for Alpha Fetoprotein

D. Chan, L. Sokoll, N. Watanabe, 2012, The International journal of biological markers.

Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease.

D. Chan, G. Hortobagyi, R. Theriault, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns.

Lori J Sokoll, Hui Zhang, Daniel W Chan, 2009, Journal of proteome research.

Variants of prostate-specific antigen separated by concanavalin A.

D. Chan, Y. M. Gao, 1991, Clinical chemistry.

Serum Fucosylated Prostate-specific Antigen (PSA) Improves the Differentiation of Aggressive from Non-aggressive Prostate Cancers

D. Chan, Hui Zhang, Zhen Zhang, 2015, Theranostics.

Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.

D. Chan, L. Sokoll, D. Bruzek, 2002, Clinica chimica acta; international journal of clinical chemistry.

Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen.

D. Chan, A. Partin, L. Sokoll, 2002, Urology.

Clinical evaluation of two direct procedures for free thyroxin, and of free thyroxin index determined nonisotopically and by measuring thyroxin-binding globulin.

D. Chan, B. Scheinin, M. Mayo, 1983, Clinical chemistry.

Hepatitis B and hepatitis C in emergency department patients.

D. Chan, R. Purcell, T. Quinn, 1992, The New England journal of medicine.

Association Between Combined TMPRSS2: ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer

John T. Wei, M. Rubin, D. Chan, 2017, JAMA oncology.

Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography–mass spectrometry

Ronald J. Moore, Stefani N. Thomas, Richard D. Smith, 2018, Nature Protocols.

Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests.

Scott R. Kronewitter, Richard D. Smith, D. Chan, 2012, Journal of proteomics.

A proteogenomic portrait of lung squamous cell carcinoma

Dana R. Valley, Matthew A. Wyczalkowski, Ratna R. Thangudu, 2021, Cell.

Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group.

William E Grizzle, William Rom, Daniel W Chan, 2009, Journal of proteome research.

Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers.

D. Chan, L. Sokoll, J. Weissfeld, 2007, Cancer research.

Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma

Guo Ci Teo, Meghan C. Burke, Jeffrey R. Whiteaker, 2020, Cell.

Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers.

Lori J Sokoll, Daniel W Chan, Alan W Partin, 2009, The Journal of urology.

Proteomic Analysis of the Air-Way Fluid in Lung Cancer. Detection of Periostin in Bronchoalveolar Lavage (BAL)

D. Chan, Hui Zhang, E. Gabrielson, 2020, Frontiers in Oncology.

Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma.

Alexander R. Pico, Matthew A. Wyczalkowski, Sara R. Savage, 2021, Cancer cell.

Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma

Guo Ci Teo, Matthew A. Wyczalkowski, Andy T. Kong, 2019, Cell.

Proteomic signatures of 16 major types of human cancer reveal universal and cancer-type-specific proteins for the identification of potential therapeutic targets

D. Chan, Hui Zhang, T. M. Lih, 2020, Journal of Hematology & Oncology.

Multi-laboratory assessment of reproducibility, qualitative and quantitative performance of SWATH-mass spectrometry

Brett Larsen, Anne-Claude Gingras, Birgit Schilling, 2016, bioRxiv.

Cancer biomarker discovery and translation: proteomics and beyond

D. Chan, V. Hristova, D. Chan, 2019, Expert review of proteomics.

Annexin XI Is Associated with Cisplatin Resistance and Related to Tumor Recurrence in Ovarian Cancer Patients

D. Chan, I. Shih, Zhen Zhang, 2007, Clinical Cancer Research.

Challenges and opportunities in the proteomic characterization of clear cell renal cell carcinoma (ccRCC): A critical step towards the personalized care of renal cancers.

D. Chan, Hui Zhang, Q. K. Li, 2019, Seminars in cancer biology.

An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer*

Li Ding, David L. Tabb, Daniel C. Liebler, 2015, Molecular & Cellular Proteomics.

Recommendations for Mass Spectrometry Data Quality Metrics for Open Access Data (Corollary to the Amsterdam Principles)*

Richard D Smith, Mark Baker, John R Yates, 2011, Molecular & Cellular Proteomics.

Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.

J. Oesterling, D. Chan, A. Partin, 1990, The Journal of urology.

Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities

Subha Madhavan, Peter B. McGarvey, Li Ding, 2019, Cell.

Biomarkers in prostate cancer: what's new?

D. Chan, D. Sartori, D. Chan, 2014, Current opinion in oncology.

Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers

K. Kinzler, B. Vogelstein, D. Chan, 2004, Clinical Cancer Research.

The Road from Discovery to Clinical Diagnostics: Lessons Learned from the First FDA-Cleared In Vitro Diagnostic Multivariate Index Assay of Proteomic Biomarkers

D. Chan, Zhen Zhang, D. Chan, 2010, Cancer Epidemiology, Biomarkers & Prevention.

The binding of a synthetic progestin, R5020 to transcortin and serum albumin.

D. Chan, W. R. Slaunwhite, W. Slaunwhite, 1977, The Journal of clinical endocrinology and metabolism.

Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI‐TOF

R W Veltri, A W Partin, A. Partin, 2004, The Prostate.

Decoding the Folding Patterns of Serum Proteins: An Alternative Strategy for Cancer Biomarker Validation?

D. Chan, Dai J. Li, D. Chan, 2010, Clinical Proteomics.

CK-MB isoforms for early risk stratification of emergency department patients.

D. Chan, G. Kelen, G. Green, 2000, Clinica chimica acta; international journal of clinical chemistry.

The prognostic significance of troponin I and troponin T.

D. Chan, J. L. Cox, G. Kelen, 1998, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

Urinary glycoproteins associated with aggressive prostate cancer

D. Chan, Hui Zhang, A. Partin, 2020, Theranostics.

Choosing an Automated Immunoassay System

Lori J Sokoll, Daniel Wan-Yui Chan, D. Chan, 2013 .

Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?

Lori J Sokoll, Daniel W Chan, Alan W Partin, 2016, The Journal of urology.

The value of serum enzymatic acid phosphatase in the staging of localized prostate cancer.

D. Chan, P. Walsh, C. Brendler, 1992, The Journal of urology.

The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.

D. Chan, A. Partin, P. Walsh, 1990, The Journal of urology.

Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay.

Lori J Sokoll, Daniel W Chan, Yee Chan-Li, 2006, Clinical chemistry.

Proteogenomic characterization of pancreatic ductal adenocarcinoma

Dana R. Valley, Matthew A. Wyczalkowski, Ratna R. Thangudu, 2021, Cell.

Proteome Profiling Outperforms Transcriptome Profiling for Coexpression Based Gene Function Prediction*

Daniel C. Liebler, Bing Zhang, Amanda G. Paulovich, 2016, Molecular & Cellular Proteomics.

A high-stringency blueprint of the human proteome

Rebekah L. Gundry, Joshua L. Justice, R. Aebersold, 2020, Nature Communications.

The prostate health index selectively identifies clinically significant prostate cancer.

John T. Wei, D. Chan, W. Catalona, 2015, The Journal of urology.

Integrated glycoprotein immobilization method for glycopeptide and glycan analysis of cardiac hypertrophy.

D. Chan, Hui Zhang, Lijun Chen, 2015, Analytical chemistry.

Precision medicine: from pharmacogenomics to pharmacoproteomics

D. Chan, A. Chambliss, D. Chan, 2016, Clinical Proteomics.

Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients.

D. Chan, L. Sokoll, F. Kuhajda, 2001, Cancer letters.

Proteomic analysis of degradation ubiquitin signaling by ubiquitin occupancy changes responding to 26S proteasome inhibition

D. Chan, Hui Zhang, Shisheng Sun, 2020, Clinical Proteomics.

Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.

John T. Wei, M. Rubin, D. Chan, 2015, The Journal of urology.

Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.

Daniel W Chan, D. Chan, I. Shih, 2009, Neoplasia.

Proteomic Analysis of Temporally Stimulated Ovarian Cancer Cells for Biomarker Discovery*

D. Chan, Hui Zhang, I. Shih, 2013, Molecular & Cellular Proteomics.

Early Detection of Cancer: Immunoassays for Plasma Tumor Markers.

D. Chan, L. Sokoll, D. Meany, 2009, Expert opinion on medical diagnostics.

Earlydetectionofcancer: immunoassaysforplasmatumor markers

D. Chan, L. Sokoll, D. Meany, 2009 .

HLA-G is a potential tumor marker in malignant ascites.

D. Chan, I. Shih, E. Wardelmann, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serum.

Richard D. Smith, D. Chan, D. Camp, 2014, Journal of proteome research.

MS-PyCloud: An open-source, cloud computing-based pipeline for LC-MS/MS data analysis

Zhen Zhang, Li Chen, Hui Zhang, 2018, bioRxiv.

Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.

D. Chan, A. Partin, L. Sokoll, 2000, The Journal of urology.

EPCA-2: a highly specific serum marker for prostate cancer.

D. Chan, B. Trock, A. Partin, 2006, Urology.

Integration of Network Biology and Imaging to Study Cancer Phenotypes and Responses

Robert Clarke, Zhen Zhang, Ye Tian, 2014, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with paclitaxel resistance

Yuan Tian, D. Chan, Hui Zhang, 2009, Proteomics. Clinical applications.

Detection of Uveal Melanoma by Multiplex Immunoassays of Serum Biomarkers.

D. Chan, Zhen Zhang, Jin Song, 2021, Methods in molecular biology.

A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [−2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness

Sudhir Srivastava, Ziding Feng, Isaac A. Mizrahi, 2010, Cancer Epidemiology, Biomarkers & Prevention.

Cancer proteomics

D. Chan, S. Liang, D. Chan, 2006, Clinical Proteomics.

Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry.

Xiao-Ying Meng, Daniel W Chan, Jing Zhao, 2005, Clinical chemistry.

Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.

Daniel W Chan, Yinhua Yu, R. Bast, 2007, Gynecologic oncology.

A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

John T. Wei, D. Chan, W. Catalona, 2011, The Journal of urology.

Can urinary PCA3 supplement PSA in the early detection of prostate cancer?

Yair Lotan, Sudhir Srivastava, Ziding Feng, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[-2]proPSA for Prostate Cancer Detection: an NCI Early Detection Research Network Validation Study

D. Chan, I. Thompson, A. Partin, 2009 .

[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.

D. Chan, I. Thompson, A. Partin, 2007, The Journal of urology.

Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.

T. Stamey, D. Chan, A. Partin, 2002, Urology.

Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.

D. Chan, R. Vessella, A. Partin, 2002, The Journal of urology.

Multicenter Evaluation of the Performance and Clinical Utility in Longitudinal Monitoring of the Bayer Immuno 1™ Complexed PSA Assay

D. Chan, R. Vessella, W. J. Allard, 1999, The International journal of biological markers.

Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays.

D. Chan, R. Vessella, A. Partin, 2000, Urology.

Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity.

E. Metter, D. Chan, P. Walsh, 1995, Urology.

A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer

D. Chan, Hui Zhang, Zhen Zhang, 2021, Theranostics.

Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer.

T. Stamey, D. Chan, A. Partin, 2003, Urology.

The use of percent free prostate specific antigen for staging clinically localized prostate cancer.

J. Pannek, D. Chan, A. Partin, 1998, The Journal of urology.

An integrated workflow for global, glyco-, and phospho-proteomic analysis of tumor tissues.

D. Chan, Hui Zhang, T. M. Lih, 2019, Analytical chemistry.

Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays.

Heng Zhu, Yan Li, Sheng-Ce Tao, 2011, Analytical chemistry.

Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer.

D. Chan, W. J. Allard, M. Schwartz, 2001, Anticancer research.

Antepartum and Postpartum Thrombomodulin Levels in Preeclamptic and Normotensive Pregnancies

D. Chan, J. Copel, C. Hsu, 1997, Journal of the Society for Gynecologic Investigation.

Thrombomodulin Levels in Preeclampsia, Gestational Hypertension, and Chronic Hypertension

D. Chan, J. Copel, C. Hsu, 1995, Obstetrics and gynecology.

The clinical application of proteomics.

Daniel W Chan, D. Chan, David A Colantonio, 2005, Clinica chimica acta; international journal of clinical chemistry.

Clinical proteomics

Daniel W. Chan, D. Chan, 2006 .

Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population.

Daniel W Chan, Alan W Partin, D. Chan, 2004, The Journal of urology.

Meaning of serum free-thyroxin values in nonthyroidal illnesses: seven methods compared.

D. Chan, E. Taylor, H. Drew, 1983, Clinical chemistry.

The Use of Laser Capture Microscopy in Proteomics Research – A Review

D. Chan, G. Kunz, D. Chan, 2004, Disease markers.

Modern Tumor Marker Discovery in Urology: Surface Enhanced Laser Desorption and Ionization (SELDI).

Daniel W Chan, Robert W Veltri, Alan W Partin, 2003, Reviews in urology.

Serum Markers in Patients with Resectable Pancreatic Adenocarcinoma: Macrophage Inhibitory Cytokine 1 versus CA19-9

D. Chan, Zhen Zhang, M. Canto, 2006, Clinical Cancer Research.

SerumMarkers in Patients with Resectable Pancreatic Adenocarcinoma : Macrophage Inhibitory Cytokine 1 versus CA 19-9

D. Chan, Zhen Zhang, M. Canto, 2006 .

Use of troponin T and creatine kinase-MB subunit levels for risk stratification of emergency department patients with possible myocardial ischemia.

D. Chan, G. Kelen, G. Green, 1998, Annals of emergency medicine.

Comparability of tumor marker immunoassays: still an important issue for clinical diagnostics?

D. Chan, D. Meany, 2008, Clinical chemistry and laboratory medicine.

Analytical and clinical evaluation of an electrochemiluminescence immunoassay for the determination of CA 125.

D. Chan, R. Molina, H. Miyachi, 1998, Clinical chemistry.

Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer

D. Chan, Zhen Zhang, L. Sokoll, 2018, Cancer Epidemiology, Biomarkers & Prevention.

Identifying Markers for Pancreatic Cancer by Gene Expression 1

B. Vogelstein, D. Chan, V. Velculescu, 2005 .

Analysis of N-glycoproteins using genomic N-glycosite prediction.

D. Chan, Hui Zhang, D. Levine, 2013, Journal of proteome research.

Proteomics: a new diagnostic frontier.

D. Chan, G. Hortin, J. Ritchie, 2006, Clinical chemistry.

Cancer Biomarker Discovery in Plasma Using a Tissue-targeted Proteomic Approach

Hui Zhang, Daniel W Chan, D. Chan, 2007, Cancer Epidemiology Biomarkers & Prevention.

Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization‐time of flight (SELDI‐TOF) mass spectrometry: Multi‐institution correlation of spectra and identification of biomarkers

O John Semmes, Daniel W Chan, Bao-Ling Adam, 2005, Proteomics.

Advancing cardiovascular biology and medicine via proteomics: Opportunities and present challenges of cardiovascular proteomics.

D. Chan, P. Ping, P. Srinivas, 2010, Circulation.

Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays.

L Liotta, C Smith, E. Petricoin, 2010, Journal of proteome research.

Mass Spectrometric Identification of Proteotypic Peptides from Clinically Used Tumor Markers

Yan Li, D. Chan, Hui Zhang, 2008, Clinical Proteomics.

Serum concentrations of cardiac troponin I in sudden death: a pilot study.

R H Hruban, J K Boitnott, S J Cina, 1998, The American journal of forensic medicine and pathology.

Multiplexed Targeted Mass Spectrometry-Based Assays for the Quantification of N-Linked Glycosite-Containing Peptides in Serum.

Stefani N. Thomas, R. Aebersold, D. Chan, 2015, Analytical chemistry.

Immunoenzymetric assay for creatine kinase MB with subunit-specific monoclonal antibodies compared with an immunochemical method and electrophoresis.

D. Chan, R. Frye, E. Taylor, 1985, Clinical chemistry.

Evaluation of Colon Cancer–Specific Antigen 2 as a Potential Serum Marker for Colorectal Cancer

D. Chan, L. Sokoll, R. Schoen, 2008, Clinical Cancer Research.

Validation of a novel model for the early detection of hepatocellular carcinoma

D. Chan, J. Marrero, L. Sokoll, 2019, Clinical Proteomics.

1431: Further Analysis of Serum Based EPCA-2 as a Specific Prostate Cancer Associated Biomarker

D. Chan, A. Partin, L. Sokoll, 2007 .

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer

John T. Wei, D. Chan, W. Catalona, 2017, BJU international.

Predicting cancer on repeat biopsy: Results of a multicenter prospective evaluation of complexed PSA

D. Chan, A. Partin, L. Sokoll, 2003 .

Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease.

D. Chan, E. Metter, P. Walsh, 1992, Cancer research.

Rapid parathyroid hormone measurement during venous localization.

D. Chan, L. Sokoll, R. Udelsman, 2000, Clinica chimica acta; international journal of clinical chemistry.

Standardization of two immunoassays for human glandular kallikrein 2.

D. Chan, A. Haese*, A. Partin, 2003, Clinical chemistry.

Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging.

E. Metter, D. Chan, A. Partin, 2002, The Journal of urology.

A NEW MODEL ELISA, BASED ON TWO MONOCLONAL ANTIBODIES, FOR QUANTIFICATION OF FATTY ACID SYNTHASE

D. Chan, L. Sokoll, Young Y. Wang, 2002, Journal of immunoassay & immunochemistry.

Two-site ELISA for the quantitative determination of fatty acid synthase.

D. Chan, L. Sokoll, F. Kuhajda, 2001, Clinica chimica acta; international journal of clinical chemistry.

Updating risk prediction tools: A case study in prostate cancer

Yuanyuan Liang, Ziding Feng, Daniel W Chan, 2012, Biometrical journal. Biometrische Zeitschrift.

Multicentre performance evaluation of the E170 Module for MODULAR ANALYTICS

Dieter J. Vonderschmitt, Roland Imdahl, Hilmar Luthe, 2004, Clinical chemistry and laboratory medicine.

Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer.

E. Fung, D. Chan, Zhen Zhang, 2013, American journal of obstetrics and gynecology.

Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay.

E. Fung, D. Chan, Zhen Zhang, 2013, Gynecologic oncology.

Fatty acid synthase as a tumor marker: its extracellular expression in human breast cancer.

D. Chan, Jinong Li, L. Sokoll, 2004, Journal of experimental therapeutics & oncology.

D. Chan, S. Liang, D. Chan, 2007, Clinica chimica acta; international journal of clinical chemistry.

Proteomic cancer biomarkers from discovery to approval: it’s worth the effort

D. Chan, Danni Li, D. Chan, 2014, Expert review of proteomics.

An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors

Yuan Tian, D. Chan, Hui Zhang, 2017, Clinical Proteomics.

PD46-02 MULTICENTER EVALUATION OF THE PROSTATE HEALTH INDEX (PHI) FOR DETECTION OF AGGRESSIVE PROSTATE CANCER IN BIOPSY-NAÏVE MEN

John T. Wei, M. Rubin, D. Chan, 2015 .

A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient

Yee Chan-Li, Daniel W. Chan, D. Chan, 2010, Breast Cancer Research and Treatment.

Clinical Assessment of a Radioimmunoassayfor Free Thyroxine Using a ModifiedTracer

D. Chan, J. Waud, 2006 .

Development and evaluation of the MiCheck test for aggressive prostate cancer.

D. Chan, D. Gillatt, J. Ruterbusch, 2020, Urologic oncology.

Glycoproteomic analysis of bronchoalveolar lavage (BAL) fluid identifies tumor-associated glycoproteins from lung adenocarcinoma.

Yan Li, D. Chan, Hui Zhang, 2013, Journal of proteome research.

Is the WHO 90:10 prostate-specific antigen (PSA) first international reference standard really 90% α1-antichymotrypsin-bound PSA and 10% free PSA?

D. Chan, L. Sokoll, D. Elliott, 2011, Clinical chemistry.

Total, free, and complexed PSA: Analysis and clinical utility

D. Chan, L. Sokoll, D. Chan, 1998 .

Can complexed PSA be used as a single test for detecting prostate cancer?

D. Chan, H. Rittenhouse, 1999, Urology.

Protein signatures of molecular pathways in non-small cell lung carcinoma (NSCLC): comparison of glycoproteomics and global proteomics

D. Chan, Hui Zhang, Q. K. Li, 2017, Clinical Proteomics.

Evaluation of the analytical and clinical performance of the Elecsys CA 15-3 immunoassay.

D. Chan, L. Sokoll, M. Untch, 2001, Clinical chemistry.

Integrated analyses of proteins and their glycans in a magnetic bead-based multiplex assay format.

D. Chan, Hui Zhang, J. Chen, 2013, Clinical chemistry.

Cancer Biomarker Assays: Performance Standards

D. Chan, A. K. Füzéry, 2017 .

Development of a glycoproteomic strategy to detect more aggressive prostate cancer using lectin-immunoassays for serum fucosylated PSA

D. Chan, Hui Zhang, L. Sokoll, 2019, Clinical Proteomics.

The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.

Ziding Feng, Daniel W Chan, Donna P Ankerst, 2013, The Journal of urology.

Using the CPTAC Assay Portal to Identify and Implement Highly Characterized Targeted Proteomics Assays.

Michael J MacCoss, Jing Chen, Brendan MacLean, 2016, Methods in molecular biology.

Tissue proteomics using chemical immobilization and mass spectrometry.

Yuan Tian, D. Chan, Hui Zhang, 2015, Analytical biochemistry.

Tyramide signal amplification for antibody-overlay lectin microarray: a strategy to improve the sensitivity of targeted glycan profiling.

D. Chan, Hui Zhang, D. Meany, 2011, Journal of proteome research.

A large-scale multi-center independent validation study of a panel of seven biomarkers for the detection of ovarian cancer.

R. Bast, E. Fung, D. Chan, 2006, Journal of Clinical Oncology.

A multiplex immunoassay of serum biomarkers for the detection of uveal melanoma

D. Chan, Zhen Zhang, L. Sokoll, 2019, Clinical Proteomics.

Multicenter comparison of the diagnostic performance of free prostate-specific antigen.

T. Stamey, J. Oesterling, D. Chan, 1996, Urology.

Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer

D. Chan, A. Partin, P. Walsh, 2005, World Journal of Urology.

MODULAR ANALYTICS: A New Approach to Automation in the Clinical Laboratory

Hiroshi Mitsumaki, Franz Keller, Gary L. Horowitz, 2005, Journal of automated methods & management in chemistry.

The chemistry of human transcortin. Improved affinity matrices for the purification of transcortin.

D. Chan, M. Sharma, W. Slaunwhite, 1977, Archives of biochemistry and biophysics.